General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises NiKang Therapeutics In Completion of US$200 Million Series C Financing

May 27, 2021
A San Diego corporate team advised the clinical stage biotech company in the transaction that will advance highly differentiated small molecules addressing difficult-to-drug targets.

NiKang Therapeutics Inc. (NiKang), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, announced the completion of an oversubscribed US$200 million series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, and Logos Capital.

Latham & Watkins LLP represented NiKang in the transaction with a San Diego-based corporate team led by San Diego partner Cheston Larson and San Diego associate Evan Youngstrom.